A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
A Phase 3, Multicenter, Long Term, Extension Study of the Safety and Efficacy of AVP-786 (Deuterated [d6] Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This was an extension study of the Phase 3 Studies 15-AVP-786-301, 15-AVP-786-302, and 17-AVP-786-305.
Eligible participants for this study had successfully completed Studies 15-AVP-786-301, 15-AVP-786-302, 12-AVR-131, or 17-AVP-786-305.
Study medication was administered orally twice daily.
Inclusion Criteria:
Exclusion Criteria:
Long Beach, California 90807, United States
Aventura, Florida 33180, United States
Lakewood, Ohio 44107, United States
Bennington, Vermont 05201, United States
Hradec KralovƩ, Czechia
Hradec KralovƩ, Czechia
Saint-Etienne, Auvergne-RhƓne-Alpes, France